Novavax (MEX:NVAX) E10: MXN-193.63 (As of Mar. 2026)


MEX:NVAX Novavax Inc MEX:NVAX
42 GF Score
Price MXN176.00
GF Value MXN70.11
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Novavax E10?

Novavax MEX:NVAX +7.32% 42 E10 is MXN-193.63 as of Mar. 2026. GuruFocus rates MEX:NVAX with a GF Score™ of 42/100 and a GF Value™ of MXN70.11 (Significantly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Novavax's adjusted earnings per share data for the three months ended in Mar. 2026 was MXN-1.082. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is MXN-193.63 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average E10 Growth Rate was 4.70% per year. During the past 5 years, the average E10 Growth Rate was -3.20% per year. During the past 10 years, the average E10 Growth Rate was -4.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Novavax was 11.20% per year. The lowest was -12.00% per year. And the median was -0.65% per year.

As of today (2026-07-03), Novavax's current stock price is MXN176.00. Novavax's E10 for the quarter that ended in Mar. 2026 was MXN-193.63. Novavax's Shiller PE Ratio of today is .


Novavax  (MEX:NVAX) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Novavax E10 Related Terms


Novavax E10 Historical Data

* Premium members only.

The historical data trend for Novavax's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novavax E10 Chart

Novavax Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -249.60 -257.00 -227.27 -269.19 -203.63

Novavax Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -276.50 -234.26 -225.20 -203.63 -193.63

MEX:NVAX vs MPLT, COAG, INBX: E10 Comparison

For the Biotechnology subindustry, Novavax's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novavax Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novavax's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Novavax's Shiller PE Ratio falls into.


MEX:NVAX
42GF Score
Novavax Inc MEX:NVAX
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novavax E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novavax's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-1.082/330.2130*330.2130
=-1.082

Current CPI (Mar. 2026) = 330.2130.

Novavax Quarterly Data

per share eps CPI Adj_EPS
201606 -107.262 241.018 -146.957
201609 -92.810 241.428 -126.941
201612 -86.591 241.432 -118.433
201703 -60.253 243.801 -81.609
201706 -57.843 244.955 -77.976
201709 -54.618 246.819 -73.072
201712 -62.846 246.524 -84.181
201803 -50.869 249.554 -67.311
201806 -46.569 251.989 -61.025
201809 -43.583 252.439 -57.010
201812 -51.051 251.233 -67.100
201903 -40.930 254.202 -53.169
201906 -32.463 256.143 -41.850
201909 -14.609 256.759 -18.788
201912 -21.312 256.974 -27.386
202003 -13.600 258.115 -17.399
202006 -6.925 257.797 -8.870
202009 -70.912 260.280 -89.965
202012 -53.708 260.474 -68.088
202103 -62.345 264.877 -77.723
202106 -94.554 271.696 -114.919
202109 -88.622 274.310 -106.683
202112 -229.347 278.802 -271.639
202203 50.972 287.504 58.544
202206 -131.371 296.311 -146.402
202209 -43.247 296.808 -48.114
202212 -44.451 296.797 -49.456
202303 -61.465 301.836 -67.244
202306 9.943 305.109 10.761
202309 -21.948 307.789 -23.547
202312 -24.952 306.746 -26.861
202403 -17.426 312.332 -18.424
202406 18.137 314.175 19.063
202409 -14.965 315.301 -15.673
202412 -10.636 315.605 -11.128
202503 59.943 319.799 61.895
202506 11.674 322.561 11.951
202509 -22.930 324.800 -23.312
202512 1.981 324.054 2.019
202603 -1.082 330.213 -1.082

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of MXN-193.63 mean?
Novavax (MEX:NVAX) has a E10 of MXN-193.63 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Novavax and its competitors.
Is Novavax's E10 too high?
Novavax's current E10 is MXN-193.63. Overall, Novavax has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novavax's E10 compare to MPLT and COAG?
Novavax's E10 of MXN-193.63 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Novavax and its competitors. Novavax's current E10 is MXN-193.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novavax stock overvalued right now?
Based on GuruFocus' analysis, Novavax (MEX:NVAX) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN70.11, compared to a current price of MXN176.00 — trading 151% above its estimated fair value. The current E10 is MXN-193.63. Novavax's overall GF Score™ is 42/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Novavax (MEX:NVAX), the current E10 is MXN-193.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novavax (MEX:NVAX) Overvalued in 2026?

Based on GuruFocus' analysis, Novavax stock appears to be overvalued. The current stock price of MXN176.00 is trading 151% above its estimated GF Value™ of MXN70.11. GuruFocus considers Novavax to be Significantly Overvalued.

Key valuation signals for MEX:NVAX:

  • E10: MXN-193.63
  • GF Value™: MXN70.11 vs. price of MXN176.00 (151% above fair value)
  • GF Score™: 42/100 with 7 warning signs

No single metric tells the full story. See the MEX:NVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novavax Business Description

Address 21 Firstfield Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
42GF Score

Get the complete analysis for MEX:NVAX

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN176.00
Price
MXN70.11
GF Value